News
Podcast: HLTH Europe and BIO key trends rundown
2+ hour, 29+ min ago (199+ words) Our editorial team delve into the key takeaways from the 2026 HLTH Europe conference and the 2026 BIO International Convention. June was a busy month for Pharmaceutical Technology's editorial team, with journalists attending several key conferences with reach across the healthcare and…...
Inocras, Aimed Bio team up for cancer treatments
6+ hour ago (212+ words) US-based precision medicine company Inocras has entered a strategic partnership with South Korean biopharmaceutical company Aimed Bio to enhance cancer drug development using whole genome intelligence. The deal includes a strategic equity investment by Aimed Bio in Inocras and a…...
EAN 2026: Real-world data supports safety and efficacy of Abb Vie's Vyalev in Parkinson's
1+ day, 25+ min ago (591+ words) Pharmaceutical Technology Abb Vie's ROSSINI (NCT06107426) study of its Parkinson's disease combination, Vyalev, has shown promise in a 12-month analysis. The data, which was presented on 29 June at the 12th Congress of the European Academy of Neurology (EAN) 2026, supported the safety and…...
Anthropic debuts AI-driven pharma R&D tool, Claude Science
1+ day, 2+ hour ago (484+ words) Claude Science launches as big tech companies increasingly eye expansion in the wider healthcare space. Tech giant Anthropic has extended its foray into the life sciences space with a new artificial intelligence (AI) tool, Claude Science, which the company says…...
Medical journal retracts Tavneos pivotal paper amid wider regulatory clampdown
1+ day, 3+ hour ago (255+ words) This further weakens Amgen's case for Tavneos' continued use on the market as the drug comes under intense regulatory scrutiny. In another blow to the future market prospects of Amgen's rare disease therapy, Tavneos (avacopan), the New England Journal of…...
Three years on: How is the industry coping with Annex 1?
2+ day, 3+ hour ago (274+ words) In Association with Thermo Fisher Scientific The revised EU GMP Annex 1 shifts the pharmaceutical industry from fragmented compliance to a holistic, comprehensive framework. Industry expert Ian Hudson shares his insights into the deeper nuances and practical impact of these changes....
Eli Lilly and Innovent agree Verzenios commercialisation deal in China
1+ day, 5+ hour ago (340+ words) Eli Lilly and Company has entered into an agreement with Innovent Biologics for the commercialisation of Verzenios (abemaciclib) in mainland China. Under this agreement, Innovent will handle the marketing, distribution and promotion'of the product within the region, while Eli Lilly…...
Lilly and Regeneron amongst first incumbents to FDA's fast-track facility scheme
1+ day, 21+ hour ago (382+ words) Seven pharma companies have been selected for the FDA Pre Check pilot " a framework intended to bolster the US drug supply chain. Eli Lilly and Regeneron are in the first slate of drugmakers included in a new US scheme to…...
Talawar Therapeutics to debut on Nasdaq with $285m as Dupixent challenger
2+ day, 3+ hour ago (499+ words) The newly formed biotech will use the funds to take its eczema bispecific, TALA-125, through to Phase IIb proof-of-concept trials. New Jersey-based biotech, Talawar Therapeutics and JATT II Acquisition have joined forces through a definitive business combination agreement " creating a…...
HLTH Europe 2026: Healthcare implementation key amid European innovation rush
2+ day, 4+ hour ago (499+ words) Experts at HLTH Europe 2026 unanimously agreed that rapid acceleration of innovation will not reveal its true benefits until healthcare services can implement new technologies. As healthcare players from Europe and further afield continue to produce potentially game-changing healthcare innovations, attendees…...